General Electric Company

Merck Sharp + Dohme Corp.

Global Life Sciences Solutions Operations UK Ltd

Jason Louis Davis

Hubert B Josien

Erik Leeming Kvam

Brian Christopher Bales

Michael John Mayer

William J Greenlee

John W Clader

Christopher Michael Puleo

Robert Jason Herr

Gregory Andrew Grossmann

Craig Patrick Galligan

Bing Li

Jason Michael Nichols

Shuangyi Wan

Ming Min Hsia

Kai Deng

Xuefeng Wang

A system is provided for separating particulates dispersed within a base fluid wherein at least one of the particulates and the base fluid is an organic liquid. The system relies on a microfluidic separation device comprising a microchannel in fluid communication across a microporous body with a collection chamber. Particulates and a portion of the base fluid traverse the microporous body under the influence of an external force field and are collected in the collection chamber. A first fluid flow having a first flow rate through the microchannel together with the microporous body operationally generate a second fluid flow within the collection chamber as base fluid and particulates traverse the microporous body and enter the collection chamber, and as base fluid re-traverses the microporous body and re-enters the microchannel, the second fluid flow having a flow rate which is a fraction of the first flow rate.

Systems for separation of particulates and associated methods and devices

A solid substrate for biological sample storage under dry-state and elution of biomolecules is provided. The dry, solid substrate is coated with saccharides, such as monosaccharides, oligosaccharides, polysaccharides or combinations thereof, and the substrate is comprised of one or more protein denaturing agents impregnated therein under a substantially dry state. A method for elution of biomolecules from biological samples is also provided. The compositions disclosed herein provide for enhanced elution and recovery of biomolecules, such as nucleic acids, from the sample. The sample is disposed on a substrate, dried to a substantially dry state; eluted from the biological sample dried on the substrate by rehydrating the substrate in an elution buffer.

Substrates and associated methods for elution of nucleic acids

This invention provides for certain bridged and fused compounds of the formulaG-L-A&#x2003;&#x2003;Ior a pharmaceutically acceptable salt, ester of solvate thereofwherein: and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Bridged and fused antidiabetic compounds

The present disclosure generally relates to dry solid matrices for the extraction, stabilization, and storage of nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the nucleic acids stored in the dry solid matrix are also described.

Formulations for nucleic acid stabilization on solid substrates

This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N&#x2014;N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders. 

Phthalazine-containing antidiabetic compounds

Growing community of inventors

Albany, NY, United States of America

Jason Louis Davis